NanoViricides Inc. (NNVC)

[Puffer]

so.... I guess it's just that when you state that there is a slim chance that big pharma will line up after a successful PhaseI/IIa of an orally deliverable, strain agnostic, treatment that cures the flu, it shows no awareness of how the industry operates nor the potential size of that market. And actually, a number of companies have already expressed interest, pending successful early stage trials. It is quite possible, given dwindling pipelines in the industry, that on the right terms a company might jump in even earlier than that in some sort of partnership. Such a deal would include an up-front payment, milestone payments, and royalties.